Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model

Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 and causes severe and often fatal acute respiratory illness in humans. No approved prophylactic and therapeutic interventions are currently available. In this study, we have developed egg yolk antibodies (immunoglobul...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Aymn T. Abbas, Sherif A. El-Kafrawy, Sayed Sartaj Sohrab, Ashraf A. Tabll, Ahmed M. Hassan, Naoko Iwata-Yoshikawa, Noriyo Nagata, Esam I. Azhar
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2020-11-01
Sarja:Vaccines
Aiheet:
MERS-COV
egg yolk antibodies
IgY against MERS-COV
vaccine
passive immunotherapy
controlling of MERS-COV infection
Linkit:https://www.mdpi.com/2076-393X/8/4/634

Internet

https://www.mdpi.com/2076-393X/8/4/634

Samankaltaisia teoksia